Cell子刊：复旦大学章真/华国强利用类器官预测直肠癌患者对放化疗的响应

Core Viewpoint - The study demonstrates that patient-derived cancer organoids (PDCO) can accurately predict the response of locally advanced rectal cancer (LARC) to chemoradiation, supporting the use of Irinotecan as a candidate for neoadjuvant therapy in LARC patients [2][4][7]. Group 1 - The research established a biobank of rectal cancer organoids (RCO) from LARC patient samples, confirming that PDCO can predict LARC responses to chemoradiation [4][7]. - The accuracy of predicting clinical outcomes using organoids was found to be 92.50% in the discovery cohort and 93.75% in the validation cohort, indicating a high predictive capability [4][7]. - The study highlighted the importance of the timing of organoid survival data collection, which significantly affects the correlation between organoid treatment responses and patient clinical outcomes [4][7]. Group 2 - The organoids exhibited both synergistic (3.91%) and antagonistic (4.69%) effects in response to combined treatment, showcasing the complexity of treatment interactions [4][7]. - Irinotecan, a topoisomerase I inhibitor, was identified as a candidate drug for neoadjuvant therapy in LARC patients, emphasizing its role in inducing apoptosis in tumor cells [4][7]. - The systematic analysis of rectal cancer organoid responses to chemoradiation may significantly influence the broader application of organoid technology in precision cancer treatment [8].